Direkt zum Inhalt
Merck
  • Laminin receptor mediates anti-inflammatory and anti-thrombogenic effects of pigment epithelium-derived factor in myeloma cells.

Laminin receptor mediates anti-inflammatory and anti-thrombogenic effects of pigment epithelium-derived factor in myeloma cells.

Biochemical and biophysical research communications (2013-12-18)
Takanori Matsui, Yuichiro Higashimoto, Sho-ichi Yamagishi
ZUSAMMENFASSUNG

Pigment epithelium-derived factor (PEDF) has anti-inflammatory and anti-thrombogenic properties both in cell culture and animal models. Although adipose triglyceride lipase (ATGL) and laminin receptor (LR) are two putative receptors for PEDF, which receptor mainly mediates the beneficial effects of PEDF is largely unknown. In this study, we addressed the issue. siRNA raised against LR (siLR) and siATGL transfection dramatically decreased LR and ATGL levels in human cultured myeloma cells, respectively. Ten nM PEDF significantly reduced vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP-1), intercellular cell adhesion molecule-1 (ICAM-1) and plasminogen activator inhibitor-1 (PAI-1) mRNA levels in siCon- or siATGL-transfected myeloma cells, whereas PEDF increased rather than decreased these gene expressions in siLR-transfected cells. Neutralizing antibody directed against LR (LR-Ab) or LR antagonist actually bound to LR and reduced mRNA levels of VEGF, MCP-1, ICAM-1 and PAI-1 in myeloma cells. Further, pre-treatment of LR-Ab or LR antagonist suppressed the binding of PEDF to LR and resultantly blocked the effects of PEDF in myeloma cells. In addition, high concentration of LR agonist mimicked the actions of PEDF on these gene expressions in myeloma cells. This study indicates that PEDF causes anti-angiogenic, anti-inflammatory and anti-thrombogenic reactions in myeloma cells through the interaction with LR. Target domain of LR agonist and antagonist might be involved in the PEDF-signaling to gene suppression in myeloma cells.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Lipase aus Candida rugosa, Type VII, ≥700 unit/mg solid
Sigma-Aldrich
Lipase aus Schweinepankreas, Type II, ≥125 units/mg protein (using olive oil (30 min incubation)), 30-90 units/mg protein (using triacetin)
Sigma-Aldrich
Lipase-Acrylharz aus Candida antarctica, ≥5,000 U/g, recombinant, expressed in Aspergillus niger
Sigma-Aldrich
Lipase aus Schweinepankreas, Type VI-S, ≥20,000 units/mg protein, lyophilized powder
Sigma-Aldrich
Lipase B Candida antarctica, rekombinant aus Aspergillus oryzae, powder, beige, ~9 U/mg
Sigma-Aldrich
Lipase aus Aspergillus niger, powder (fine), ~200 U/g
Sigma-Aldrich
Lipase aus Aspergillus oryzae, solution, ≥100,000 U/g, white, beige
Sigma-Aldrich
Lipase aus Candida rugosa, lyophilized powder, ≥40,000 units/mg protein
Sigma-Aldrich
Lipase, immobilisiert aus Candida antarctica, beads, slightly brown, >2 U/mg
Sigma-Aldrich
Lipase aus Candida sp., recombinant, expressed in Aspergillus niger
Sigma-Aldrich
Lipase aus Rhizomucor miehei, ≥20,000 U/g
Sigma-Aldrich
Lipase aus Pseudomonas cepacia, powder, light beige, ≥30 U/mg
Sigma-Aldrich
Lipase aus Weizenkeimen, Type I, lyophilized powder, 5-15 units/mg solid
Sigma-Aldrich
Lipase aus Rhizopus oryzae, powder (fine), ~10 U/mg
Sigma-Aldrich
Lipase aus Aspergillus oryzae, lyophilized, powder, white, ~50 U/mg
Sigma-Aldrich
Lipase aus Pseudomonas sp., Type XIII, lyophilized powder, ≥15 units/mg solid
Sigma-Aldrich
Lipase aus Candida rugosa, powder, yellow-brown, ≥2 U/mg
Sigma-Aldrich
Lipase aus Candida rugosa, lyophilized, powder (fine), 15-25 U/mg
Sigma-Aldrich
Lipase aus Mucor miehei, lyophilized powder, ≥4,000 units/mg solid (using olive oil)
Sigma-Aldrich
Lipase aus Mucor miehei, powder, slightly brown, ~1 U/mg
Sigma-Aldrich
Lipase aus Rhizopus niveus, powder (fine), ≥1.5 U/mg
Sigma-Aldrich
Lipase aus Mucor javanicus, lyophilized powder, ≥300 units/mg solid (using olive oil)
Sigma-Aldrich
Lipase A Candida antarctica, rekombinant aus Aspergillus oryzae, powder, beige, ~2 U/mg